Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | RGS12 | O14924 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367189 | 1.00 | CYP3A4 (0.52) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL5367760 | 0.89 | EGFR (0.58) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL5367754 | 0.89 | EGFR (0.58) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL7164752 | 0.83 | MAPT (0.45) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL3243232 | 0.82 | MEN1 (0.57) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL3243227 | 0.82 | MEN1 (0.57) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL3242612 | 0.80 | MEN1 (0.62) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL3242618 | 0.80 | MEN1 (0.62) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL3242616 | 0.80 | MEN1 (0.62) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 | |
| SCHEMBL25800807 | 0.79 | MEN1 (0.74) | CYP3A4MAPTSMN1; SMN2CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217737-B2 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2004-12-02 | — | — | US | disclosed |
| US-6596878-B2 | Protein kinase inhibitor compositio; used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR. | YISSUM RESEARCH & DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY (IL) | 2003-07-22 | — | — | US | disclosed |
| US-20020068687-A1 | Methods and compositions for inhibiting cell proliferative disorders | CHEN HUI (US) | 2002-06-06 | — | — | US | disclosed |
| US-6225346-B1 | FOR THERAPY AND PROPHYLAXIS OF CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS ASSOCIATED WITH PARTICULAR TYROSINE KINASES BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | ERBB2, EGFR, MKI67 | CYP3A4 4877/4885MAPT 2232/4885SMN1; SMN2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.